The U.S. Food and Drug Administration has approved the first medicine in a new class of sleep drugs, clearing the way for a treatment that targets the underlying biology of narcolepsy rather than just its symptoms. The decision, announced Wednesday, marks a major shift for patients with Type 1 narcolepsy, a rare condition marked by sudden sleep attacks and muscle weakness.
The drug, developed by Japan-based Takeda Pharmaceutical, will be sold under the brand name Orzeyful. It works by amplifying “orexin-2,” a protein that helps regulate alertness, arousal and appetite. In two large clinical trials, patients taking the medicine showed significantly better wakefulness and fewer episodes of cataplexy, the sudden loss of muscle control that is a hallmark of Type 1 narcolepsy, compared with those on a placebo. The drug was also generally well tolerated.
“For too long, people with narcolepsy type 1 have had to manage a complex, lifelong neuropsychiatric condition with treatments that only address pieces of it,” said Tiffany Farchione, director of the psychiatry division in the FDA’s main drug review office, in a statement. “This new drug is the first medicine that impacts the underlying biology of the disease, treating narcolepsy type 1 as a whole.”
Patient advocates echoed that sentiment. Julie Flygare, CEO of the advocacy group Project Sleep, called the approval “a historic moment that expands our treatment choices and gives me great hope for the future.” Takeda CEO Julie Kim said the clearance opens a “new chapter for the narcolepsy type 1 community” and could “potentially redefine how this disease is managed and how people feel on treatment.”
Wall Street analysts see a large commercial opportunity. Jefferies estimates Orzeyful could cost between $142,000 and $250,000 per patient per year, with peak annual sales reaching roughly $2 billion. Takeda has not disclosed pricing, and a spokesperson said access details would be shared when the drug becomes commercially available.
Because Orzeyful alters brain chemistry and affects neurological networks tied to reward, it must first undergo review by the Drug Enforcement Administration. That scheduling process could take up to 90 days, after which the drug can officially launch.
A crowded race to follow
Takeda will not have the field to itself for long. Ireland-based Alkermes is the closest competitor, having recently launched a global late-stage program for its orexin-boosting drug alixorexton across both Type 1 and Type 2 narcolepsy. The company is also studying the drug for idiopathic hypersomnia, a related sleep disorder. Alkermes CEO Blair Jackson said the goal is to win approval across all three conditions, so doctors do not have to prove a specific diagnosis to insurers, offering more flexibility for patients.
Other drugmakers, including Eisai and Eli Lilly, are also entering the orexin space. Lilly recently completed a $6.3 billion buyout of Centessa Pharmaceuticals to gain access to its orexin program. For now, the FDA’s decision gives Takeda a head start, but analysts say pricing and payer coverage will be the key factors to watch as the launch unfolds. For patients, the arrival of a first-in-class therapy offers a new reason for optimism in a field that has seen little innovation for decades.